Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IC 43

Next Previous
X
Search
Drug Profile

IC 43

Alternative Names: IC-43; OprF-OprI vaccine - Valneva; PE-001; PE-002; Pseudomonas aeruginosa vaccine - Valneva; VLA 43

Latest Information Update: 02 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Valneva
  • Class Antibacterials; Pseudomonas vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pseudomonal infections

Most Recent Events

  • 31 Aug 2016 Discontinued - Phase-II/III for Pseudomonal infections (Prevention) in Czech Republic, Spain, Germany, Belgium, Hungary and Austria (IM) because phase II/III trial results did not confirm a positive vaccine effect
  • 21 Mar 2016 Valneva plans a phase III trial for Pseudomonal infections
  • 01 Dec 2015 Valneva completes a phase II/III trial in Pseudomonal infections in Austria, Belgium, Czech Republic, Germany, Hungary and Spain (IM) (NCT01563263)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top